MSCs for Prevention of MI-induced HF

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

Also called NCT05043610

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 420 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05043610
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05043610. Randomized; single masking; primary purpose treatment. Start 2021-09-15 (actual); primary completion 2024-11-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MSCs for Prevention of MI-induced HF
Acronym
PREVENT-TAHA8
Condition
Myocardial Infarction, Acute
Condition
Myocardial Infarction First
Condition
Myocardial Infarction, Anterior Wall
Condition
Cardiac Remodeling, Ventricular
Condition
STEMI
Condition
Regenerative Medicine
Condition
Heart Failure
Intervention (Biological)
Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)
Intervention (Other)
Conventional Treatment
Lead sponsor
Shiraz University of Medical Sciences (class: other)
Collaborator
National Institute for Medical Research and Development (class: other)

Record details

Record id
cardio:ct-nct05043610
Content hash
02a37aedac20b83efc46bbffb445d211abfe8e99b25d19087d6e1738ec178711